These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37794797)

  • 1. Tucidinostat restores CCR4 expression in adult T-cell leukemia/lymphoma.
    Kawata T; Shimizu T; Shindo T; Fujiwara K; Morimoto S; Watanabe M
    Haematologica; 2024 Mar; 109(3):1007-1009. PubMed ID: 37794797
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular analysis of loss of CCR4 expression during mogamulizumab monotherapy in an adult T cell leukemia/lymphoma patient.
    Taguchi M; Imaizumi Y; Sasaki D; Higuchi T; Tsuruda K; Hasegawa H; Taguchi J; Sawayama Y; Imanishi D; Hata T; Yanagihara K; Yoshie O; Miyazaki Y
    Ann Hematol; 2015 Apr; 94(4):693-5. PubMed ID: 25338968
    [No Abstract]   [Full Text] [Related]  

  • 3. CCR4 mutations associated with superior outcome of adult T-cell leukemia/lymphoma under mogamulizumab treatment.
    Sakamoto Y; Ishida T; Masaki A; Murase T; Yonekura K; Tashiro Y; Tokunaga M; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Inagaki H
    Blood; 2018 Aug; 132(7):758-761. PubMed ID: 29930010
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunohistochemistry for CCR4 C-terminus predicts CCR4 mutations and mogamulizumab efficacy in adult T-cell leukemia/lymphoma.
    Fujii K; Sakamoto Y; Masaki A; Murase T; Tashiro Y; Yonekura K; Utsunomiya A; Ito A; Kusumoto S; Iida S; Ueda R; Ishida T; Inagaki H
    J Pathol Clin Res; 2021 Jan; 7(1):52-60. PubMed ID: 33022137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.
    Sakamoto Y; Fujii K; Murase S; Nakano S; Masaki A; Murase T; Kusumoto S; Iida S; Utsunomiya A; Ueda R; Ishida T; Inagaki H
    Int J Hematol; 2019 Oct; 110(4):389-392. PubMed ID: 31468320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CCR4 drives ATLL jail break.
    Shannon KM
    J Exp Med; 2014 Dec; 211(13):2485. PubMed ID: 25512583
    [No Abstract]   [Full Text] [Related]  

  • 7. CCR4 frameshift mutation identifies a distinct group of adult T cell leukaemia/lymphoma with poor prognosis.
    Yoshida N; Miyoshi H; Kato T; Sakata-Yanagimoto M; Niino D; Taniguchi H; Moriuchi Y; Miyahara M; Kurita D; Sasaki Y; Shimono J; Kawamoto K; Utsunomiya A; Imaizumi Y; Seto M; Ohshima K
    J Pathol; 2016 Apr; 238(5):621-6. PubMed ID: 26847489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cDNA-Based Mutation Screening Using a Combination of High-Resolution Melting Curve and Fragment Analysis Facilitates Efficient CCR4 Mutation Analysis in Adult T-Cell Leukemia/Lymphoma.
    Mizuta S; Yamane N; Mononobe S; Komai T; Koba Y; Kawata T; Ukyo N; Tamekane A; Watanabe M
    Am J Clin Pathol; 2020 Jul; 154(2):236-241. PubMed ID: 32367127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.
    Kitadate A; Ikeda S; Abe F; Takahashi N; Shimizu N; Matsue K; Tagawa H
    Haematologica; 2018 Jan; 103(1):126-135. PubMed ID: 29025909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gain-of-function CCR4 mutations in adult T cell leukemia/lymphoma.
    Nakagawa M; Schmitz R; Xiao W; Goldman CK; Xu W; Yang Y; Yu X; Waldmann TA; Staudt LM
    J Exp Med; 2014 Dec; 211(13):2497-505. PubMed ID: 25488980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant expression of Fra-2 promotes CCR4 expression and cell proliferation in adult T-cell leukemia.
    Nakayama T; Hieshima K; Arao T; Jin Z; Nagakubo D; Shirakawa AK; Yamada Y; Fujii M; Oiso N; Kawada A; Nishio K; Yoshie O
    Oncogene; 2008 May; 27(23):3221-32. PubMed ID: 18071306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosing of a phase I study of KW-0761, an anti-CCR4 antibody, for adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Suzuki R
    J Clin Oncol; 2010 Aug; 28(23):e404-5; author reply e406. PubMed ID: 20566994
    [No Abstract]   [Full Text] [Related]  

  • 13. Loss of CCR4 antigen expression after mogamulizumab therapy in a case of adult T-cell leukaemia-lymphoma.
    Ohno N; Kobayashi S; Ishigaki T; Yuji K; Kobayashi M; Sato K; Watanabe N; Tojo A; Uchimaru K
    Br J Haematol; 2013 Dec; 163(5):683-5. PubMed ID: 23998261
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral histone deacetylase inhibitor tucidinostat (HBI-8000) in patients with relapsed or refractory adult T-cell leukemia/lymphoma: Phase IIb results.
    Utsunomiya A; Izutsu K; Jo T; Yoshida S; Tsukasaki K; Ando K; Choi I; Imaizumi Y; Kato K; Kurosawa M; Kusumoto S; Miyagi T; Ohtsuka E; Sasaki O; Shibayama H; Shimoda K; Takamatsu Y; Takano K; Yonekura K; Makita S; Taguchi J; Gillings M; Onogi H; Tobinai K
    Cancer Sci; 2022 Aug; 113(8):2778-2787. PubMed ID: 35579212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma.
    Yamamoto K; Utsunomiya A; Tobinai K; Tsukasaki K; Uike N; Uozumi K; Yamaguchi K; Yamada Y; Hanada S; Tamura K; Nakamura S; Inagaki H; Ohshima K; Kiyoi H; Ishida T; Matsushima K; Akinaga S; Ogura M; Tomonaga M; Ueda R
    J Clin Oncol; 2010 Mar; 28(9):1591-8. PubMed ID: 20177026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffuse panbronchiolitis after humanized anti-CCR4 monoclonal antibody therapy for relapsed adult T-cell leukemia/lymphoma.
    Kato K; Miyamoto T; Numata A; Nakaike T; Oka H; Yurino A; Kuriyama T; Mori Y; Yamasaki S; Muta T; Takenaka K; Iwasaki H; Teshima T; Akashi K
    Int J Hematol; 2013 Mar; 97(3):430-2. PubMed ID: 23397210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Furin-dependent CCL17-fused recombinant toxin controls HTLV-1 infection by targeting and eliminating infected CCR4-expressing cells in vitro and in vivo.
    Hiyoshi M; Okuma K; Tateyama S; Takizawa K; Saito M; Kuramitsu M; Araki K; Morishita K; Okada S; Yamamoto N; Biragyn A; Yamaguchi K; Hamaguchi I
    Retrovirology; 2015 Aug; 12():73. PubMed ID: 26289727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of TP53 mutations in adult T-cell leukemia/lymphoma.
    Sakamoto Y; Ishida T; Masaki A; Murase T; Takeshita M; Muto R; Iwasaki H; Ito A; Kusumoto S; Nakano N; Tokunaga M; Yonekura K; Tashiro Y; Iida S; Utsunomiya A; Ueda R; Inagaki H
    Br J Haematol; 2021 Nov; 195(4):571-584. PubMed ID: 34405395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a novel Indium-111 radiolabeled mogamulizumab targeting CCR4 for imaging adult T-cell leukemia/lymphoma in vivo.
    Shimizu Y; Koyasu S; Suzukida M; Izumi K; Kidera E; Shindo T; Saga T; Ono M; Takaori-Kondo A; Nakamoto Y
    Ann Nucl Med; 2022 Mar; 36(3):319-326. PubMed ID: 35034259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful treatment with tucidinostat in a patient with relapsed adult T-cell leukemia/lymphoma following allogeneic hematopoietic stem cell transplantation].
    Moriki A; Ito S; Horikita F; Tsutsumi Y
    Rinsho Ketsueki; 2024; 65(1):18-23. PubMed ID: 38311384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.